9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2019
The DOI matches its Crossref record; 77 of the 81 references it cites were found in a registry or an index.
Abstract
The American Diabetes Association (ADA) “Standards of Medical Care in Diabetes” includes ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA’s clinical practice recommendations, please refer to the Standards of Care Introduction. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although SGLT2 inhibitor use was not incorporated into American Diabetes Association guidelines until 2019,48”
From Association of race/ethnicity, gender, and socioeconomic status with sodium-glucose cotransporter 2 inhibitor use among patients with diabetes in the US (2021) · cites this paper as [48]
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · cited 1×
“Metformin is effective and safe, is inexpensive, and may reduce risk of cardiovascular events and death (40).”
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Riddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
Maruthur, N. M., Tseng, E., Hutfless, S., Wilson, L. M., Suarez-Cuervo, C., Berger, Z., Chu, Y., Iyoha, E., Segal, J. B., & Bolen, S. (2016) · Annals of Internal Medicine · doi:10.7326/m15-2650 · Cited by 682
Threshold-based insulin-pump interruption for reduction of hypoglycemia
Bergenstal, R. M., Klonoff, D. C., Garg, S. K., Bode, B. W., Meredith, M., Slover, R. H., Ahmann, A. J., Welsh, J. B., Lee, S. W., & Kaufman, F. R. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303576 · Cited by 652
Research works printed but not linked: 6
- Peters, 2013, American Diabetes Association/JDRF Type 1 Diabetes Sourcebook
- Chiang, 2014, Type 1 diabetes through the life span: a position statement of the American Diabetes Association
- Lexicon Pharmaceuticals . FDA to review ZynquistaTM (sotagliflozin) as potential treatment for type 1 diabetes [Internet], 2018. Available from http://www.lexpharma.com/media-center/news/673-fda-to-review-zynquista-sotagliflozin-as-potential-treatment-for-type-1-diabetes. Accessed 30 September 2018
- Institute for Clinical and Economic Review . Controversies in the management of patients with type 2 diabetes [Internet], December 2014. Available from https://icer-review.org/wp-content/uploads/2015/03/CEPAC-T2D-Final-Report-December-22.pdf. Accessed 9 November 2018
- Lipska, 2018, Association of initiation of basal insulin analogs vs neutral protamine Hagedorn insulin with hypoglycemia-related emergency department visits or hospital admissions and with glycemic control in patients with type 2 diabetes, 53
- Lipska, 2017, Human insulin for type 2 diabetes: an effective, less-expensive option, 23
Cited by
Items 401–500 of 773
Caterina, R. D., Patti, G., Westerbergh, J., Horowitz, J. D., Ezekowitz, J. A., Lewis, B. S., Lópes, R. D., McMurray, J. J. V., Atar, D., Bahit, M. C., et al. (2020) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaa140 · Cited by 11
“13 While insulin treatment in diabetes is usually adopted in more severe and advanced stages of the disease, 14 that report rather pro-vocatively showed that non-insulin-treated diabetes apparently entails no higher thromboembolic risk compared with no diabetes in anticoagulated patients.”
Li, X., Zhang, Q., Zhou, X., Guo, S., Jiang, S., Zhang, Y., Zhang, R., Dong, J., & Liao, L. (2021) · Aging · doi:10.18632/aging.202945 · Cited by 11
“…(EASD) and the American Diabetes Association (ADA) recommend SGLT-2 inhibitors as a combination therapy with other antihyperglycemic drugs at any stage of T2DM and when metformin is not tolerated or ineffective, SGLT-2 inhibitors was recommend as an acceptable alternative to metformin [7–8].”
Temporelli, P. L. (2024) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suae011 · Cited by 13
Csatordai, M., Benkő, R., Matúz, M., Bor, A., Lengyel, C., & Doró, P. (2019) · Diabetic Medicine · doi:10.1111/dme.14117 · Cited by 10
Michaud, T. L., Siahpush, M., King, K. M., Ramos, A. K., Robbins, R., Schwab, R. J., Clarke, M. A., & Su, D. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107944 · Cited by 10
Bando, H. (2020) · MOJ Clinical & Medical Case Reports · doi:10.15406/mojcr.2020.10.00341 · Cited by 10
Polavarapu, N. K., Kale, R. M., Sethi, B. K., Sahay, R. K., Phadke, U., Ramakrishnan, S., Mane, A., Mehta, S. C., & Shah, S. P. (2020) · Drugs - Real World Outcomes · doi:10.1007/s40801-020-00206-7 · Cited by 13
GLP-1 Receptor Agonists and Cardiovascular Disease: What Do Clinicians Need to Know?
Hayat, J., Shah, N. P., Agarwala, A., Khan, M. S., & Butler, J. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01214-6 · Cited by 11
Zhang, P., Shen, Y., Xu, X. H., Ding, B., Yan, R., Wang, H.-Y., Xie, X., Ma, J., & Hu, Y. Y. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v15.i7.1489 · Cited by 11
Nichols, G. A., Romo‐LeTourneau, V., Vupputuri, S. X., & Thomas, S. M. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13683 · Cited by 10
Diabetes, Therapeutic Inertia, and Patients’ Medication Experience
Bzowyckyj, A. S., & Begert, J. E. (2020) · Diabetes Spectrum · doi:10.2337/ds19-0019 · Cited by 10
How gut microbiota relate to the oral antidiabetic treatment of type 2 diabetes
Hung, W., & Hung, W.-C. (2020) · Medicine in Microecology · doi:10.1016/j.medmic.2020.100007 · Cited by 11
Zarei, L., Peymani, P., Moradi, N., Kheirandish, M., Mirjalili, M., & Zare, M. (2020) · International Journal of Health Policy and Management · doi:10.34172/ijhpm.2020.152 · Cited by 10
KUMAR, K. M. P., Seshadri, K., Sosale, A., Deb, P., Modi, K., Gopal, R. A., Vijaya Kumar, G., Moses, C. R. A., Abhyankar, M., & Revenkar, S. (2021) · Cureus · doi:10.7759/cureus.13020 · Cited by 14
Valle, C. G.-D., Marco‐Expósito, J. F., Bosch‐Sierra, N., Zaragozá, B., Solá, E., Montoya‐Castilla, I., Morillas, C., & Bañuls, C. (2022) · Journal of Clinical Nursing · doi:10.1111/jocn.16270 · Cited by 10
Drewe, J., Boonen, G., & Culmsee, C. (2022) · Phytomedicine · doi:10.1016/j.phymed.2022.154060 · Cited by 10
Quality of care in type 2 diabetes in Iran; a cross-sectional study using patient-level data
Davari, M., Bayazidi, Y., Kebriaeezadeh, A., Esteghamati, A., Bandarian, F., Kashi, Z., Bahar, A., & Yousefi, S. (2022) · BMC Endocrine Disorders · doi:10.1186/s12902-022-01034-2 · Cited by 10
Wang, Z., Gao, L., Guo, X., Feng, C., Deng, K., Lian, W., Feng, M., Bao, X., & Xing, B. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00736 · Cited by 10
A Behavioral Perspective of Therapeutic Inertia: A Look at the Transition to Insulin Therapy
Guzman, S. (2020) · Diabetes Spectrum · doi:10.2337/ds19-0024 · Cited by 10
Marx, N., Rydén, L., Brosius, F. C., Ceriello, A., Cheung, M., Cosentino, F., Green, J., Kellerer, M., Koob, S., Kosiborod, M., et al. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108092 · Cited by 10
Wong, C. K. H., Man, K. K. C., Chan, E. W., Wu, T., Tse, E. T. Y., Wong, I. C. K., & Lam, C. L. K. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001346 · Cited by 10
Chen, J., Peng, Y., Chen, C.-S., Tseng, C., Chen, P.-C., Lee, T.-I., Lu, Y.-C., Yang, Y., Lin, C., Hung, Y.-J., et al. (2020) · PeerJ · doi:10.7717/peerj.9998 · Cited by 12
“(American Diabetes Association 2019; Diabetes Association Of The Republic Of China 93 Taiwan 2019; Garber et al. 2018; McGuire et al. 2016) 94 Sodium-glucose cotransporter-2 (SGLT2) inhibitors are a newer class of oral antidiabetic 95 drugs (OADs) that inhibit glucose reabsorption at the early…”
BackgroundKalra, S., Unnikrishnan, A., Bantwal, G., Das, S., Polavarapu, N. K., & Gaurav, K. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01002-4 · Cited by 10
Veroniki, A. A., Seitidis, G., Stewart, L. A., Clarke, M. J., Smith, C. T., Mavridis, D., Yu, C. H. Y., Moja, L., Straus, S. E., & Tricco, A. C. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-058034 · Cited by 12
Glucose-Lowering Medication Use in CKD: Analysis of US Medicare Beneficiaries Between 2007 and 2016
Zhao, J. Z., Weinhandl, E. D., Carlson, A. M., & St. Peter, W. L. (2021) · Kidney Medicine · doi:10.1016/j.xkme.2020.09.016 · Cited by 9
Nguyen, C., Luthra, R., Kuti, E. L., & Willey, V. J. (2020) · Current Medical Research and Opinion · doi:10.1080/03007995.2020.1832455 · Cited by 9
Overhydration: A cause or an effect of kidney damage and how to treat it
Szymczak, A., Kusztal, M. A., & Krajewska, M. (2021) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/132035 · Cited by 9
Li, B., Li, X., Zeng, Y., Zhou, Z., Zhao, D., Qin, F., Zhang, B., Yao, W., Mao, Y., Zhou, L., et al. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2278082 · Cited by 9
“Although several classes of orally available anti-T2DM drugs, including metformin, sulfo-nylureas, and sitagliptin, have beneficial effects in patients with T2DM, these drugs mainly focus on a single target, which often results in adverse effects (American Diabetes Association, 2018; Tsang, 2012).”
Metabolic syndrome in children
Tagi, V. M., Samvelyan, S., & Chiarelli, F. (2020) · Minerva Pediatrics · doi:10.23736/s0026-4946.20.05834-x · Cited by 9
Zhao, Z., Jin, P., Zhang, Y., Hu, X. Y., Tian, C., & Liu, D. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.826684 · Cited by 10
Yang, Y., Wang, L., Zhou, Y., He, Y., Lin, S., Zeng, Y., Zhou, Y., Li, W., He, Z., Zhao, Q., et al. (2022) · Regenerative Biomaterials · doi:10.1093/rb/rbac023 · Cited by 11
Safety of COVID-19 Vaccines among Patients with Type 2 Diabetes Mellitus: Real-World Data Analysis
Kim, H. J., Lee, S. J., Sa, S., Bae, J. H., Song, G., Lee, C. W., Kim, J. H., Shim, S. R., Hong, M., & Han, H. W. (2023) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2022.0129 · Cited by 9
A Retrospective Time Trend Study Of Diabetes Overtreatment In Geriatric Patients
Wojszel, Z. B., & Kasiukiewicz, A. (2019) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s221179 · Cited by 9
Haymana, C., Sönmez, A., Demirci, İ., Yaylalı, G. F., Nuhoğlu, İ., Sancak, S., Yılmaz, M., Altuntaş, Y., Dınççağ, N., Sabuncu, T., et al. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108556 · Cited by 9
Hankosky, E. R., Katz, M. L., Fan, L., Liu, D., Chinthammit, C., Brnabic, A. J. M., & Eby, E. L. (2023) · Current Medical Research and Opinion · doi:10.1080/03007995.2023.2205795 · Cited by 9
“Many people with T2D may require treatment intensification with injectables, including insulin for their T2D management, when oral antihyperglycemic agents (OAHs) and lifestyle interventions fail to provide glycemic control 2,3 .”
BackgroundEditorial: Physical Activity and Type 1 Diabetes
JENDLE, J. H., & Riddell, M. C. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00860 · Cited by 9
McGinty, E. E., Murphy, K. A., Dalcin, A., Stuart, E. A., Wang, N., Dickerson, F., Gudzune, K. A., Jerome, G. J., Thompson, D., Cullen, B., et al. (2020) · Journal of General Internal Medicine · doi:10.1007/s11606-020-06137-x · Cited by 10
Panhotra, S., & Gupta, P. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.147418 · Cited by 10
Rubab, H., Aziz, F., Gul, R. B., & Froelicher, E. S. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-093798 · Cited by 8
Bataglini, C., Mariano, I. R., Azevedo, S. C. S. F., Freire, V. N., Natali, M. R. M., Pedrosa, M. M. D., Peralta, R. M., de Sá‐Nakanishi, A. B., Bracht, L., de Godoi, V. A. F., et al. (2021) · Journal of Applied Biomedicine · doi:10.32725/jab.2021.025 · Cited by 8
Braha, A., Albai, A., Timar, B., Cipu, D., Vasiluță, L., Potre, O., & Timar, R. Z. (2021) · Medicina · doi:10.3390/medicina58010021 · Cited by 9
Đorđević, M. M., Tolić, A., Rajić, J., Mihailović, M., Јovanović, J. A., Uskoković, A. S., Grdović, N., Đorđević, M. B., Mišić, D. M., Šiler, B., et al. (2022) · Journal of Functional Foods · doi:10.1016/j.jff.2022.104975 · Cited by 8
Giving Prizes (reward) and Its Influence on Student Learning Motivation
Faysal, M., Tabroni, I., Jie, L., Jixiong, C., Nitin, M., & Bradford, S. (2023) · Journal Emerging Technologies in Education · doi:10.55849/jete.v1i2.464 · Cited by 8
“…someone as an award for doing activities in accordance with their (Aparicio, 2019), both in terms of quality and in terms of quantity and the reply can produce satisfaction or increase the possibility of doing better and reward is also one of the educational (American Diabetes Association, 2019).”
BackgroundRai, P., Dwibedi, N., Rowneki, M., Helmer, D. A., & Sambamoorthi, U. (2019) · PubMed · Cited by 13
Rasul, S., Geist, B. K., Brath, H., Baltzer, P., Sundar, L. K. S., Pichler, V., Mitterhauser, M., Kautzky‐Willer, A., & Hacker, M. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-001135 · Cited by 8
Update to Evidence-Based Secondary Prevention Strategies After Acute Coronary Syndrome
FITCHETT, D. H., Leiter, L. A., Lin, P., Pickering, J., Welsh, R. C., Stone, J. A., Grégoire, J. C., McFarlane, P. A., Langer, A., Gupta, A. K., et al. (2020) · CJC Open · doi:10.1016/j.cjco.2020.04.002 · Cited by 8
Can Monoclonal Antibodies against CGRP Offer New Treatment Options for Type 2 Diabetes?
Riera, C. E. (2020) · Journal of Diabetes and Clinical Research · doi:10.33696/diabetes.1.028 · Cited by 8
Raju, A., Pimple, P. M., Stafkey-Mailey, D., Farrelly, E., & Shetty, S. S. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01173-0 · Cited by 8
Interconception Preventive Care and Recurrence of Pregnancy Complications for Medicaid-Insured Women
Gregory, E. F., Passarella, M. A., Levine, L. D., & Lorch, S. A. (2022) · Journal of Women s Health · doi:10.1089/jwh.2021.0355 · Cited by 8
Katsiki, N., & Mikhailidis, D. P. (2019) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2019.04.011 · Cited by 8
Franch‐Nadal, J., Mata‐Cases, M., Ortega, E., Real, J., Gratacòs, M., Vlacho, B., Vallés, J. A., & Mauricio, D. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8091389 · Cited by 8
Cardiovascular Risk Reduction in Type 2 Diabetes: Therapeutic Potential of Dapagliflozin
Avgerinos, I., Liakos, A., Τσάπας, Α., & Bekiari, E. (2019) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s190356 · Cited by 9
Mukai, J., Yoshiyama, A., & Kubota, R. (2020) · Journal of Pharmaceutical Health Care and Sciences · doi:10.1186/s40780-020-00160-0 · Cited by 8
Time in suboptimal glycemic control over 10 years for patients newly diagnosed with type 2 diabetes
An, J., Nichols, G. A., Qian, L., Harrison, T. N., Li, Z., Munis, M. A., Wei, R. X., Weiss, T., Rajpathak, S. N., & Reynolds, K. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107607 · Cited by 9
Shi, F., Shen, L., Pan, M.-M., Ma, L., Zhang, C., Gu, Z., Ma, J., & Li, H. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00756 · Cited by 8
Giorda, C. B., Orsi, E., Cosmo, S. D., Bossi, A. C., Guerzoni, C., Cercone, S., Gilio, B., & Cavalot, F. L. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00871-5 · Cited by 9
Xiao, B., Xiao, Y., Ning, H., Han, X., Li, W., Ma, Y., Zhao, N., Du, G., Dong, Y. J., Jung, J. H., et al. (2020) · Medicinal Chemistry Research · doi:10.1007/s00044-020-02628-y · Cited by 8
“Although the exact etiology of T2DM is still unclear, glycemic management is primarily suggested as the major therapeutic approach for T2DM, because poor glucose control is positively correlated to the risk of major complications such as cardiovascular disease, further insulin damage, etc. (American Diabetes Associati…”
BackgroundLee, Y.-M., Lee, S., Kim, T. H., Park, E.-J., Park, Y.-A., & Jang, J. (2020) · Cardiology Journal · doi:10.5603/cj.a2020.0140 · Cited by 8
Morales, J., Kuritzky, L., Lavernia, F., & Santiago, M. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1857603 · Cited by 8
Kok, A., Hariram, A., Webb, D., & Amod, A. (2021) · Journal of Endocrinology Metabolism and Diabetes of South Africa · doi:10.1080/16089677.2021.1897227 · Cited by 8
Modeling Structure–Activity Relationship of AMPK Activation
Drewe, J., Küsters, E., Hammann, F., Kreuter, M. H., Boss, P., & Schöning, V. (2021) · Molecules · doi:10.3390/molecules26216508 · Cited by 9
A Peptide in a Pill – Oral Semaglutide in the Management of Type 2 Diabetes
Selvarajan, R., & Subramanian, R. (2023) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s385196 · Cited by 8
Tuttle, K. R., & McGill, J. B. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13986 · Cited by 8
A Review of the Renoprotective Effects of Novel Antidiabetic Agents
Leite, K., Long, A. M., Ostroff, M. L., Borges, L., & Braden, G. L. (2020) · Journal of Pharmacy Practice · doi:10.1177/0897190020902344 · Cited by 9
Tofé, S., Argüelles, I., Mena, E., Serra, G., Codina, M., Urgelés, J. R., García, H., & Pereg, V. (2021) · Endocrine and Metabolic Science · doi:10.1016/j.endmts.2021.100082 · Cited by 9
Advances in Diabetes Treatment — Once-Weekly Insulin
Gottlieb, P. A., & Michels, A. W. (2020) · New England Journal of Medicine · doi:10.1056/nejme2031596 · Cited by 8
Increasing Vitamin B12 Screening Among Patients With Type 2 Diabetes on Long-Term Metformin Therapy
Mays, E. P. (2021) · Clinical Diabetes · doi:10.2337/cd20-0108 · Cited by 7
From Glucose Control to Multifaceted Benefits: The Rise of Modern Sulphonylureas in Diabetes Care
Shrestha, D., Dhingra, A., Shakya, S., & Tuladhar, J. (2025) · Current Diabetes Reports · doi:10.1007/s11892-025-01582-6 · Cited by 8
“Gliclazide also has shown a favorable cardiovascular safety profile and ability to protect against renal complications, with the lowest hypoglycemic event rate [60].”
Advances in GLP-1 receptor agonists delivery systems for obesity and diabetes
Abbasi, M., Sun, K., Huggins, K. W., Heath, B., DeLoit, H., McGinness, L., & Mccamy, K. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.01.035 · Cited by 10
Cardiovascular outcome trials of glucose-lowering therapies
Khunti, K., Davies, M. J., & Seidu, S. (2020) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2020.1763796 · Cited by 7
Aleksić, S., Eisenberg, R. E., Tsomos, E., Anaraki, S. Z., Japp, E., Upadhyay, L., Mowrey, W. B., Akalin, E., & Zonszein, J. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108221 · Cited by 7
Dіrgar, E., & Olgun, N. (2021) · İnönü Üniversitesi Sağlık Hizmetleri Meslek Yüksek Okulu Dergisi · doi:10.33715/inonusaglik.842256 · Cited by 7
Кобалава, Ж. Д., Medovchshikov, V., Yeshniyazov, N., & Хасанова, Э. Р. (2019) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2019-11-98-111 · Cited by 7
Alavudeen, S. S., Khobrani, M. A., Dhanapal, C. K., Mir, J. I., Alshahrani, S. M., Khan, N. A., & Alhossan, A. (2019) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2019.11.023 · Cited by 7
Kato, E. T., Das, S. R., & McGuire, D. K. (2020) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2019.12.010 · Cited by 9
Renal outcomes with the newer antidiabetes drugs: the era before and after CREDENCE
Rajani, A., Sahay, M., Bhattacharyya, A., & Amar, A. (2020) · Diabetic Medicine · doi:10.1111/dme.14262 · Cited by 7
Preexisting diabetes, metformin use and long-term survival in patients with prostate cancer
Linkevičiūtė-Ulinskienė, D., Patašius, A., Kinčius, M., Zabulienė, L., & Smailytė, G. (2020) · Scandinavian Journal of Urology · doi:10.1080/21681805.2020.1798502 · Cited by 7
Cohen, C. M., Hallén, N., Chodick, G., Bourvine, L., Waner, T., & Karasik, A. (2020) · Value in Health Regional Issues · doi:10.1016/j.vhri.2020.05.003 · Cited by 7
Classification of drug use patterns
Righolt, C. H., Zhang, G., & Mahmud, S. M. (2020) · Pharmacology Research & Perspectives · doi:10.1002/prp2.687 · Cited by 7
“37 Patients with the same mean dose could have very different patterns of use (constant, increasing, decreasing, and varying), and we showed that this pattern of use is relevant as the clinical characteristics differ between these groups.”
BackgroundAlnaim, L. S., Altuwaym, R. A., Aldehan, S. M., & Alquraishi, N. M. (2021) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2021.08.010 · Cited by 7
“According to the International Diabetes Federation (IDF), in Saudi Arabia, the estimated percentage of total adult population living with diabetes was 18.32%, while in children and adolescents (0–19 years) it was 0.26% (IDF, 2019; Ministry of Health KSA, 2013).”
InfluentialPrevalence of Lipohypertrophy and its Associations in Insulin-Treated Diabetic Patients
Nawaz, A., Hasham, M. A., Shireen, M., & Iftikhar, M. (2022) · Pakistan Journal of Medical Sciences · doi:10.12669/pjms.39.1.6134 · Cited by 7
Moke, E. G., Omogbai, E. K. I., Osagie-Eweka, S. E., Uchendu, A. P., Obayuwana, M. O., Okoro-Akpandu, E., & Ben‐Azu, B. (2023) · Laboratory Animal Research · doi:10.1186/s42826-023-00159-2 · Cited by 10
Neumiller, J. J., Chen, G., Newsome, C. C., Hughes, S., Lazarus, P. J., & White, J. R. (2019) · Journal of Diabetes Science and Technology · doi:10.1177/1932296819883291 · Cited by 7
Beyond basal-bolus insulin regimen: Is it still the ultimate chance for therapy in diabetes?
Giugliano, D., Bellastella, G., Maiorino, M. I., & Esposito, K. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107922 · Cited by 7
Hemodynamic response during hyperbaric treatment on skeletal muscle in a type 2 diabetes rat model
Goto, N., Fujita, N., Nino, W., Hisatsune, K., Ochi, R., Nishijo, H., & Urakawa, S. (2020) · Biomedical Research · doi:10.2220/biomedres.41.23 · Cited by 7
Chen, T., Zhou, L., Wang, K., Ma, X., Wu, H., Liu, X., Tong, J., Cai, B., & Ji, Q. (2020) · Clinical Therapeutics · doi:10.1016/j.clinthera.2020.06.006 · Cited by 7
Fazioli, K., Rind, D. M., Guzauskas, G. F., Hansen, R. N., & Pearson, S. D. (2020) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2020.26.9.1072 · Cited by 7
Nadeau, H. C. G., Maxted, M. E., Madhavan, D., Pierce, S., Feghali, M. N., & Scifres, C. (2020) · American Journal of Perinatology · doi:10.1055/s-0040-1718579 · Cited by 8
Jensen, T., Olesen, K. K. W., Caterina, R. D., Würtz, M., Kristensen, S. D., & Mæng, M. (2020) · Vascular Pharmacology · doi:10.1016/j.vph.2020.106809 · Cited by 7
GLP1 agonists beyond glycemic control—redefining their role
Chowdhury, S., & Goswami, S. (2020) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-020-00879-4 · Cited by 7
Tesega, W. W., Genet, S., Netasan, G., Tarekegn, G., Girma, F., Chalchisa, D., Belay, Y., Geto, Z., & Dejenie, T. A. (2021) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s306433 · Cited by 8
The DIVE/DPV registries: evolution of empagliflozin use in clinical practice in Germany
Bramlage, P., Tittel, S. R., Wagner, C., König, K., Raddatz, D., Weber-Lauffer, R., Erath, D., Hilgenberg, J., Spies, C., Danne, T., et al. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001486 · Cited by 6
Kumar, S. (2023) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_2114_22 · Cited by 6
Elharram, M., de Moura, C. S., Abrahamowicz, M., Bernatsky, S., Behlouli, H., Raparelli, V., & Pilote, L. (2020) · International Journal of Cardiology · doi:10.1016/j.ijcard.2020.03.025 · Cited by 6
Seo, D. H., Ha, K. H., Kim, S. H., & Kim, D. J. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2020.777 · Cited by 6
Things we do for no reason™: Routinely holding metformin in the hospital
Cohen, D. A., Ricotta, D. N., & Parikh, P. D. (2021) · Journal of Hospital Medicine · doi:10.12788/jhm.3644 · Cited by 6
Carullo, N., Zicarelli, M. T., Casarella, A., Nicotera, R., Castagna, A., Urso, A., Presta, P., Andreucci, M., Russo, E., Bolignano, D., et al. (2021) · International Journal of General Medicine · doi:10.2147/ijgm.s305491 · Cited by 6
Wood, S. J., Bell, J. S., Magliano, D. J., Shaw, J. E., Cesari, M., & Ilomäki, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.886834 · Cited by 6
Lee, S. J., Bae, S. H., Jeon, S., Ji, H. Y., & Han, S. (2023) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15891 · Cited by 6
Trueman, C., Shin, E. H., Donovan, A., McAdam‐Marx, C., & Coan, C. (2023) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2023.29.12.1275 · Cited by 6
Metadata
- Authors
- American Diabetes Association
- Corresponding author
- American Diabetes Association
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2018-12-07
- Volume
- 42
- Issue
- Supplement_1
- Pages
- S90-S102
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W4212810717
- Cited by
- 739
- References
- 81
- Citations by year
- 2026: 12 · 2025: 28 · 2024: 30 · 2023: 47 · 2022: 69 · 2021: 126 · 2020: 246 · 2019: 181
- FWCI
- 21.27
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- glycemic control, pharmacotherapy, antidiabetic drugs, treatment goals, quality of care, clinical guidelines
- MeSH terms
- Blood Glucose, Diabetes Mellitus, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Societies, Medical, United States, Practice Guidelines as Topic, Standard of Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.